Tony Hagen

Tony Hagen is senior managing editor for The Center for Biosimilars®.

Tanvex Presents Positive Findings for Trastuzumab Candidate at ESMO

September 20, 2021

Investigators said TX05 met pathologic complete response criteria for equivalence to the originator product, Herceptin. The biosimilar candidate also fell within objective response rate, immunogenicity, safety, and tolerability margins for similarity.